Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts

Anticancer Research

Volumn 28, Issue 1 A, 2008, Pages 179-186

  Nakahira, Shin ^a,b   Nakamori, Shoji ^a,c,d   Tsujie, Masanori ^a,c   Takeda, Setsuo ^a   Sugimoto, Keishi ^b   Takahashi, Yuji ^a   Okami, Jiro ^a   Marubashi, Shigeru ^a   Miyamoto, Atsushi ^a   Takeda, Yutaka ^a   Nagano, Hiroaki ^a   Dono, Keizo ^a   Umeshita, Koji ^a   Sakon, Masato ^a   Monden, Morito ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANSAI ROSAI HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

^d OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

5 fluorouracil; Combination chemotherapy; Gemcitabine; Human equilibrative nucleotide transporter; In vivo; Pancreatic cancer; S 1; Schedule dependent effect

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FLUOROURACIL; GEMCITABINE;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG SYNERGISM; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FLUOROURACIL; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; OXONIC ACID; PANCREATIC NEOPLASMS; RNA, MESSENGER; TEGAFUR; TRITIUM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 40549099699     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117, 1991.
2. Thomas DM and Zalcberg JR: 5-Fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol 25: 887-895, 1998.
3. Baldwin SA, Mackey JR, Cass CE and Young JD: Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today 5: 216-224, 1999.
4. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR and Cass CE: Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58: 4349-4357, 1998.
5. Pressacco J, Wiley JS, Jamieson GP, Erlichman C and Hedley DW: Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis. Br J Cancer 72: 939-942, 1995.
6. Pressacco J, Mitrovski B, Erlichman C and Hedley DW: Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res 55: 1505-1508, 1995.
7. Rauchwerger DR, Firby PS, Hedley DW and Moore MJ: Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 60: 6075-6079, 2000.
8. Tsujie M, Nakamori S, Nakahira S, Takeda S, Takahashi Y, Hayashi N, Okami J, Nagano H, Dono K, Umeshita K, Sakon M and Monden M: Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model. Pancreas 33: 142-147, 2006.
9. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N and Fukushima M: Antitumor activity of 1 M tegafur - 0.4 M 5-chloro-2,4-dihydroxypyridine - 1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602-2606, 1996.
10. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996.
11. Tatsumi K, Fukushima M, Shirasaka T and Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78: 748-755, 1987.
12. Takechi T, Fujioka A, Matsushima E and Fukushima M: Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer 38: 1271-1277, 2002.
13. Ogawa M: Novel anticancer drugs in Japan. J Cancer Res Clin Oncol 125: 134-140, 1999.
14. Schoffski P: The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 15: 85-106, 2004.
15. Furuse J, Okusaka T, Funakoshi A, Boku N, Yamao K, Ohkawa S and Saito H: A phase II study of S-1 in patients with metastatic pancreatic cancer (abstract 4104). Proc Am Soc Clin Oncol 23: 333, 2005.
16. Kulke MH: Advanced pancreatic cancer: is there a role for combination therapy? Expert Rev Anticancer Ther 3: 729-739, 2003.
17. El-Rayes BF and Philip PA: Systemic therapy for advanced pancreatic cancer. Expert Rev Anticancer Ther 2: 426-436, 2002.
18. Bruckner H, Zhou G, Haenel P, Szrajer L, Greenspan E and Kurbacher C: Ex vivo ATP tumor testing of gemcitabine for combination chemotherapy and biochemical modulation (abstract 2116). Proc Am Assoc Cancer Res 39: 310a, 1998.
19. Ren Q, Kao V and Grem JL: Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2′-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res 4: 2811-2818, 1998.
20. Ueno H, Okusaka T, Ikeda M, Ishiguro Y, Morizane C, Matsubara J, Furuse J, Ishii H, Nagase M and Nakachi K: A phase I study of combination chemotherapy with gemcitabine and oral S-I for advanced pancreatic cancer. Oncology 69: 421-427, 2005.
21. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H and Saisho H: Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 94: 1575-1579, 2006.
22. Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T, Okabe H, Fujioka A, Nakano K, Ohshimo H, Takeda S and Shirasaka T: Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 13: 693-698, 1998.
23. Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G and Peters GJ: Schedule-dependent antitumor effect of gemcitabine in an in vivo model system. Semin Oncol 22: 42-46, 1995.
24. Tsujie M, Nakamori S, Okami J, Hayashi N, Hiraoka N, Nagano H, Dono K, Umeshita K, Sakon M and Monden M: Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway. Exp Cell Res 289: 143-151, 2003.
25. Finke J, Fritzen R, Ternes P, Lange W and Dolken G: An improved strategy and a useful housekeeping gene for RNA analysis from formalin-fixed, paraffin-embedded tissues by PCR. Biotechniques 14: 448-453, 1993.
26. Garcia-Manteiga J, Molina-Areas M, Casado FJ, Mazo A and Pastor-Anglada M: Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 9: 5000-5008, 2003.
27. Wang H, Li M, Rinehart JJ and Zhang R: Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res 10: 1633-1644, 2004.
28. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004.
29. Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
30. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG and Benson AB, 3rd: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270-3275, 2002.
31. Goldin A: Combined chemotherapy. Oncology 37(Suppl 1): 3-8, 1980.
32. Choi DS, Handa M, Young H, Gordon AS, Diamond I and Messing RO: Genomic organization and expression of the mouse equilibrative, nitrobenzylthioinosine- sensitive nucleoside transporter 1 (ENT1) gene. Biochem Biophys Res Commun 277: 200-208, 2000.